Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy
Diabetic Retinopathy, Vitreomacular Traction
About this trial
This is an interventional other trial for Diabetic Retinopathy focused on measuring Methotrexate, proliferative diabetic retinopathy
Eligibility Criteria
Inclusion Criteria: - Patients with diabetic tractional macular detachment or combined tractional- rhegmatogenous retinal detachment Exclusion Criteria: Previous vitreoretinal surgery. Pregnant or lactating female. Co-existing pathology that might induce PVR such as penetrating ocular trauma or uveitis, co-existing congenital anomalies or hereditary vitreoretinopathies
Sites / Locations
- ophthalmology department, Minia university hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Methotrexate group
Control group
methotrexate group will receive 40 mg of MTX in 500 ml of irrigation fluid during vitrectomy and 250 ug intra-silicone oil injection at the end of vitrectomy
control group will not receive MTX in irrigation fluid during vitrectomy nor intra-silicone at the end of vitrectomy